1635PCOMPARISON OF THE 2007 AND 2013 ASCO/CAP GUIDELINES FOR HER2 ISH TESTING IN INVASIVE BREAST CANCER PATIENTS

1635PCOMPARISON OF THE 2007 AND 2013 ASCO/CAP GUIDELINES FOR HER2 ISH TESTING IN INVASIVE BREAST CANCER PATIENTS

Abstract Aim: The American Society of Clinical Oncology and the College of American Pathologists have issued joint updated comprehensive recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. In relation to the in situ hybridization (ISH) scoring, HER2 positivi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv566-iv566
Hauptverfasser: Salido, M., Puiggros, A., Corominas, J.M., Iglesias, M., Rodriguez-Rivera, M., Melero, C., Tusquets Trias Bes, I., Albanell, J., Serrano, S., Servitja Tormo, S., Espinet, B.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Aim: The American Society of Clinical Oncology and the College of American Pathologists have issued joint updated comprehensive recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer. In relation to the in situ hybridization (ISH) scoring, HER2 positivity is redefined as HER2 copy number of ≥6.0 signals/cell, or HER2/CEP17 ratio of ≥2, instead of 2.2. The equivocal category includes cases with a copy number >4 to
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdu359.7